Answers are grounded in this paper and cite their sources.
Very early-onset inflammatory bowel disease (VEO-IBD) is a genetically and phenotypically unique entity from adult-onset or older pediatric IBD and a growing subset of IBD. In most cases, a child with VEO-IBD presents with similar manifestations like an older patient with IBD, but some may present with a highly aggressive course and some cases may present with features of immunodeficiency. It differs from adult-onset IBD in many aspects such as disease behavior, location of the disease, and disease type and mostly occurs due to genetic causes. Next-generation genome sequencing could be an important tool for diagnosing genetic defects, especially in children with VEO-IBD disease. Most of the children with VEO-IBD do not comply with conventional therapy, and they ultimately need early immunosuppressive therapy that may grossly affect the child growth and development and also may possess long-term risks of cancer and opportunistic infections.
No takes yet. Share an insight, caveat, or question.
Alam et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: